NEUROTOXICOLOGICAL PROPERTIES OF THE COMPOUND AV-19 FOR PROPHYLAXIS AND TREATMENT OF COMPLICATIONS OF DIABETES MELLITUS

The article presents the results of a study of the neurotoxicological profile of the new compound AB-19, acting on collagen glycation end products (AGE) and their receptors (RAGE), for the prevention and treatment of diabetes complications. The multi-test method «S. Irwin» was used. The test results were evaluated in parallel groups receiving the substance in doses starting with the average effective dose (ED50) and with a multiple increase by 5, 10, 20 and 50 times. It was found that the compound AB-19 in doses of 20, 100 and 200 mg / kg does not affect the functional and behavioral status of animals. However, with an increase to 400 mg / kg, typical manifestations of intoxication were observed: a decrease in muscle tone, hypothermia, sedation, tachypnea. As a result of the study, it was revealed that the neurotoxicological properties of the compound AB-19 are characterized by dose-dependent activity. A minimum toxic dose of 400 mg / kg ≤ Td_min ≤ 1000 mg / kg was also indicated.

1. Ionova T.I. et al. Quality of life and problems associated with hypoglycemia in patients with type 2 diabetes mellitus on the background of oral hypoglycemic therapy. Clinical medicine. - 2013. - Vol. 91. - Iss. 9 (in Russian).

2. Global report on diabetes. Geneva: World Health Organization; 2018. License: CCBY-NC-SA3. 0IGO (in Russian).

3. Sergienko A.V. Clinical pharmacology of oral hypoglycemic drugs in the training of students of pharmaceutical universities / Sergienko A.V., Ivashev M.N., Lysenko T.A., Arlt A.V., Zatsepina E.E. et al./ International Journal of Experimental Education. -2012.- Iss. 10. – Pp. 17 – 20 (in Russian).

4. Dedov I.I. et al. Diabetes mellitus: diagnosis, treatment, prevention. – 2011 (in Russian).

5. Ramasamy R. et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. – 2005. – Vol. 15. – Iss. 7. –Pp. 16R-28R.

6. Smirnova O.M., Kononenko I.V. Hypoglycemic therapy of type 2 diabetes: problems of long-term safety. Endocrinology. - 2016. - Vol. 4-5. - Pp. 32-43 (in Russian).

7. Makarova M.N. Methodological approaches to the assessment of neurotoxicity of substances / Makarova M.N., Makarov V.G., Shekunova E.V./ Journal of the Scientific Center for the Examination of Medical Devices. -2017. – Vol. 7. – Iss. 2 (in Russian).

8. European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes// European Treaty Series - No. 123.

9. National standard of the Russian Federation GOST R 33044-2014 “Principles of good laboratory practice” (approved by Order of the Federal Agency for Technical Regulation and Metrology, dated November 20, 2014, in Russian).

10. Guidelines for conducting preclinical research of medicines. Part one / ed. Mironov A.N. -M: Grif and K. - 2012. - Pp. 80-93 (in Russian).

11. Irwin S. Drug screening and evaluation of new compounds in animals. In: Nodin J.H., Siegler P.E., eds. Animal and clinical techniques in drug evaluation. Chicago: Year Book Medical Publishers; 1964. - Pp. 36–54.

12. Irwin S. Determination of variability in drug response / S. Irwin / Psychosomatics. – 1964. –Vol. 5. – Pp. 174-179.

13. Irwin, S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behABioral and physiologic state of the mouse [Text] / S. Irwin / Psychopharmacologia. – 1968. – Vol. 13. – Iss. 3. – p. 222-257.

14. Kovalev D.G., Bugaeva L.I., Ozerov A.A. Neurotoxicological profile of new adenine derivatives with antiviral activity. Saratov Scientific Medical Journal. – 2010. - Vol. 6. - Iss. 2 (in Russian).

15. Kuznetsova V.A. et al. Method for in vitro evaluation of the antiglycemic activity of new substances. Volgograd Scientific Medical Journal. – 2014. – Iss. 3 (in Russian).